리제네론 파마슈티컬스, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionWELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2
Latest Disclosed Ownership82 shares
Latest Disclosed Value $ 43,050
WELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2 reports 4.65% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On August 26, 2025 - WELLS FARGO VARIABLE TRUST - Wells Fargo VT Index Asset Allocation Fund Class 2 filed a NPORT-P form disclosing ownership of 82 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $43,050 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 86 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -4.65% during the quarter. The current value of the position is $52,107 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 82 -4 -4.65 43 -20.37 0.0634
2025-05-27 2025-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 86 -3 -3.37 55 -14.29 0.0822
2025-02-26 2024-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 89 -7 -7.29 63 -37.00 0.0907
2024-11-25 2024-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 96 -2 -2.04 101 -2.91 0.1392
2024-08-26 2024-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 98 -2 -2.00 103 7.29 0.1476
2024-05-28 2024-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 100 -7 -6.54 96 3.23 0.1380
2024-02-28 2023-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 107 -2 -1.83 94 4.49 0.1409
2023-11-22 2023-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 109 -14 -11.38 90 1.14 0.1443
2023-08-28 2023-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 123 1 0.82 88 -12.00 0.1333
2023-05-25 2023-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 122 -2 -1.61 100 12.36 0.1555
2023-02-24 2022-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 124 -3 -2.36 89 2.30 0.1430
2022-11-29 2022-09-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 127 -4 -3.05 87 12.99 0.1427
2022-08-29 2022-06-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 131 0 0.00 77 -15.38 0.1179
2022-05-31 2022-03-31 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 131 -3 -2.24 91 8.33 0.1197
2022-02-28 2021-12-31 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 134 -4 -2.90 85 1.20 0.1018
2021-11-24 2021-09-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 138 -5 -3.50 84 5.06 0.1038
2021-08-27 2021-06-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 143 -9 -5.92 80 11.27 0.0974
2021-06-01 2021-03-31 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 152 -8 -5.00 72 -7.79 0.0907
2021-03-01 2020-12-31 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 160 -9 -5.33 77 -18.09 0.0981
2020-11-25 2020-09-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 169 -1 -0.59 95 -11.32 0.1269
2020-08-28 2020-06-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 170 42 32.81 106 70.97 0.1489
2020-05-28 2020-03-31 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 128 -3 -2.29 63 26.53 0.0978
2020-02-28 2019-12-31 NP REGENERON PHARMACEUTICALS USD.001 EC 75886F107 131 -8 -5.76 49 28.95 0.0681
2019-11-26 2019-09-30 NP REGENERON PHARMACEUTICALS USD.001 EC US75886F1075 139 139 39 0.0534
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.